The Itch That Science Finally Cracked

A Disease More Complex Than We Thought:

For decades, canine atopic dermatitis was understood as a Th2-dominated allergic disease "a straightforward story of allergen exposure, IgE production, and mast cell degranulation". Treat the allergy, calm the Th2 response, stop the itch. Simple enough. Except it was never quite that simple, and the science of 2025 has made that abundantly clear.

The International Committee on Allergic Diseases of Animals (ICADA) now defines cAD as a chronic, usually pruritic, T-cell-dependent dermatitis resulting from epidermal barrier abnormalities, allergen sensitisation, and microbial dysbiosis. That definition alone tells you something important: this is not one problem. It is three interlocking problems, each feeding the others in a vicious cycle.

The epidermal barrier is the first domino. In atopic dogs, the stratum corneum has an abnormal lipid composition and reduced filaggrin expression, the protein that normally holds skin cells together like mortar between bricks. Without it, transepidermal water loss increases, the skin dries out, and allergens that would normally bounce off the surface instead penetrate into the deeper layers. Once inside, they are captured by dendritic cells, which carry them to the draining lymph nodes and present them to T lymphocytes. The immune system, primed for battle, launches its response.

But which response? This is where the new science gets genuinely surprising. A landmark 2025 review by Wichtowska and Olejnik in the International Journal of Molecular Sciences confirmed what clinicians had long suspected: cAD is not a simple Th2 disease. It is a heterogeneous, multi-axial immune disorder. In acute lesions, yes, Th2 cytokines dominate IL-4, IL-13, and crucially, IL-31. But in chronic lesions, the picture shifts. Th1 cytokines (IFN-γ, IL-2), Th17 cytokines (IL-17, IL-23), and Th22 cytokines (IL-22) all enter the fray. Some dogs show a 'pure' Th2 profile; others show a mixed response. The disease is not one entity_ it is a spectrum.

🔬 KEY MECHANISM:  When keratinocytes detect allergen penetration, they release 'alarmin' cytokines 'TSLP, IL-25, and IL-33' that activate dendritic cells and innate lymphoid cells (ILC2s), triggering the full inflammatory cascade before the adaptive immune system even arrives.

And then there is IL-31; the molecule that has become the star of veterinary dermatology. Secreted by Th2 cells and mast cells, IL-31 binds to a receptor complex (IL-31RA and OSMRβ) that is highly expressed on cutaneous sensory nerve endings. When IL-31 docks onto those receptors, it fires a signal directly into the nervous system. The dog scratches. It cannot help itself. IL-31 is, in the most literal sense, the itch switch and understanding it has opened the door to some of the most targeted therapies veterinary medicine has ever seen.

The Genetic Smoking Gun:

Why do some dogs get cAD and others do not? Why are French Bulldogs, Boxers, Labrador Retrievers, and West Highland White Terriers so disproportionately affected? The answer, it turns out, is written in their DNA, and in 2025, scientists finally found the most compelling genetic clue yet.

A team led by Oliver Forman at Wisdom Panel (Mars Petcare) conducted what is arguably the largest genome-wide association study ever performed in veterinary dermatology. They analysed the genomes of 29,011 dogs; 14,378 with confirmed cAD and 14,633 healthy controls, using commercial DNA testing data from Wisdom Panel and samples from the MARS PETCARE BIOBANK. The scale of the study gave it statistical power that previous research simply could not match.

The result was a clear, statistically significant signal on canine chromosome 38. Whole-genome resequencing of that region revealed a splice donor variant in a gene called SLAMF1, signalling Lymphocytic Activation Molecule 1. SLAMF1 encodes a transmembrane receptor that plays important roles in immune cell function, particularly in regulating T-cell and NK-cell responses. When the splice donor is disrupted, the gene's normal function is compromised, and the immune system, it seems, becomes predisposed to the kind of dysregulation that drives atopic disease.

📊 STUDY SCALE:  29,011 dogs analysed across 116 breeds. The SLAMF1 splice variant was confirmed in French Bulldogs and Boxers, and found in free-roaming dogs worldwide; suggesting it is a global contributor to cAD risk, not a breed-specific quirk.

The implications are profound. First, SLAMF1 is now a pharmaceutical target, a specific molecular handle that drug developers can design therapies around. Second, the variant is a breeding biomarker: breeders can now, in principle, use DNA testing to make informed decisions that reduce the prevalence of cAD in future generations. Third, and perhaps most importantly for the clinician, this discovery validates what many had long suspected: cAD has a strong genetic component, and not all atopic dogs are the same at the molecular level. Personalised medicine, in veterinary dermatology, is no longer a distant aspiration.

A New Drug Arrives:

In 2026 the United States Food and Drug Administration approved a drug that veterinary dermatologists had been watching with considerable interest: NUMELVI™ (atinvicitinib tablets), developed by Merck Animal Health. The press release described it as 'the first and only second-generation Janus kinase (JAK) inhibitor indicated for the control of pruritus associated with allergic dermatitis in dogs.' That description deserves unpacking, because the distinction between first- and second-generation JAK inhibitors matters enormously.

JAK inhibitors work by blocking the Janus kinase enzymes [JAK1, JAK2, JAK3, and TYK2] that sit inside cells and relay signals from cytokine receptors on the cell surface. When a cytokine like IL-31 binds to its receptor, it activates JAK enzymes, which activate STAT transcription factors, which travel to the nucleus and switch on inflammatory genes. Block the JAK, and you interrupt that entire cascade. The itch signal never reaches its destination!

The first-generation veterinary JAK inhibitor, oclacitinib (Apoquel), has been available since 2013 and has transformed the management of cAD. But oclacitinib inhibits multiple JAK enzymes, which means it can interfere with immune functions beyond the ones driving itch and inflammation. Atinvicitinib is different. It is at least ten times more selective for JAK1 than for JAK2, JAK3, or TYK2. In human medicine, second-generation selective JAK1 inhibitors are already considered the standard of care for conditions like rheumatoid arthritis and atopic dermatitis. NUMELVI brings that same precision to the veterinary clinic.

💊 NUMELVI AT A GLANCE:  Once-daily oral tablet · Dogs ≥6 months and ≥2 kg · Dose: 0.8–1.2 mg/kg · ≥10× selective for JAK1 vs JAK2/JAK3/TYK2 · No vaccination schedule adjustment needed · Longest shelf life among JAK inhibitor tablets in veterinary medicine · Available at veterinary clinics from spring 2026.

The safety profile is important to understand. NUMELVI is not for use in dogs with serious infections, and clinicians should be alert to the possibility of opportunistic infections including demodicosis and interdigital furunculosis. Dogs with a history of recurrent demodicosis require careful risk-benefit assessment before treatment. As with other JAK inhibitors, new neoplastic conditions have been reported in dogs treated with this drug class, though the clinical significance in the veterinary context continues to be evaluated. The drug has not been evaluated beyond 28 days in field studies, and its safety in breeding, pregnant, or lactating dogs has not been established.

The Evidence Speaks:

A drug is only as good as its evidence, and the pivotal randomised controlled trial for atinvicitinib (NUMELVI™); published in Veterinary Dermatology in September 2026 by Jirjis and colleagues; provides compelling data. The study enrolled 61 client-owned dogs with confirmed cAD, randomised into three groups: once-daily dosing (q.d., n=21), a twice-daily to once-daily transition (b.i.d.→q.d., n=21), and placebo (n=19).

The primary endpoint was treatment success, defined as a ≥50 per cent reduction from baseline on the Pruritus Visual Analogue Scale (PVAS) at day 28. The results were striking. In the once-daily group, 87.5% of dogs achieved treatment success (p=0.011 vs control). In the b.i.d.→q.d. group, 73.3% succeeded (p=0.033). In the placebo group, just 23.1 per cent met the threshold, a reminder of how significant spontaneous variation can be in this disease, and why controlled trials matter.

Secondary endpoints reinforced the picture. 80% of once-daily dogs showed a ≥2-point reduction in PVAS (versus 16.7% of controls, p=0.042). Skin lesion scores measured by the CADESI-04 (the gold-standard veterinary dermatology assessment tool) also improved significantly in the once-daily group (p=0.046). Clinical pathology values remained within reference ranges throughout the 28-day study, and the drug was well-tolerated across the cohort.

📈 TRIAL RESULTS:  Once-daily atinvicitinib: 87.5% treatment success · b.i.d.→q.d.: 73.3% · Placebo: 23.1% · 80% of q.d. dogs showed ≥2-point PVAS reduction · CADESI-04 significantly improved · All clinical pathology within reference ranges.

Choosing the Right Tool:

NUMELVI does not arrive into a vacuum. The treatment landscape for cAD is already rich, and understanding where atinvicitinib fits requires knowing what came before it. The 2025 CareVet Clinical Outcomes Report (a survey of practising DVMs) found that more than 55% of respondents selected JAK inhibitors as their primary treatment for cAD, reporting clinical effectiveness in roughly 77% of cases. But JAK inhibitors are not the only option, and they are not always the right one.

Lokivetmab (Cytopoint) takes a different approach entirely. Rather than blocking intracellular signalling, it is a monoclonal antibody that neutralises IL-31 directly in the bloodstream, catching the itch signal before it ever reaches the cell. Administered by injection every four to eight weeks, it achieves 94% success by day 7 in published studies, with 70 to 80% of moderate cases maintaining sustained relief for the full dosing interval. Its minimal systemic effects make it particularly suitable for dogs with comorbidities or those on complex medication regimens.

Oclacitinib (Apoquel), the first-generation JAK inhibitor, remains a workhorse of veterinary dermatology. With more than a decade of clinical data behind it, it provides rapid itch relief, often within hours, and maintains good control in up to 72% of dogs with consistent daily dosing. For refractory cases that do not respond adequately to either agent alone, a 2026 retrospective study of 44 dogs suggested that combining oclacitinib and lokivetmab may offer additional benefit, a phased approach that adjusts treatment intensity to the clinical phase.

And then there is allergen-specific immunotherapy (ASIT), the only treatment in this entire landscape that is genuinely disease-modifying rather than symptom-controlling. ASIT works by gradually exposing the immune system to increasing concentrations of the allergens driving the disease, inducing tolerance through upregulation of regulatory T cells and suppression of allergen-specific inflammatory pathways. It is slow (clinical evaluation is recommended after at least 12 months) but in the right patient, it can achieve long-term control in 60% or more of cases, with the possibility of reducing or eliminating the need for symptomatic drugs entirely.

The Gut-Skin Connection:

The study, led by Vera Felten at the University of Zurich in collaboration with Texas A&M University and the University of Glasgow, enrolled 46 client-owned dogs with naturally occurring cAD. 40 completed the study. The treatment group received daily oral lyophilised faecal microbiota transplantation (FMT) capsules plus three monthly rectal FMT administrations over 90 days. The control group received placebo capsules with sham handling. Concomitant symptomatic therapies were permitted in both groups.

The results were striking. At month two, CADESI-04 scores were significantly lower in the FMT group (7±6 versus 16±12, p=0.006), and this improvement was maintained at month three (8±6 versus 15±12, p=0.020). Sustained responders, defined as dogs achieving ≥50% CADESI-04 improvement at both month two and month three, were far more common in the FMT group: 35% versus just 5% in the placebo group (p=0.044). Perhaps most practically significant for owners and clinicians alike, medication scores were significantly lower in the FMT group at both month two and month three, suggesting that microbiome restoration may reduce the burden of symptomatic drug use. FMT was well-tolerated throughout.

🦠FMT TRIAL RESULTS: Sustained responders: 35% (FMT) vs 5% (placebo) · CADESI-04 significantly lower at months 2 and 3· Medication scores significantly reduced · Well-tolerated · Funded by Wellcome Trust and AKC Canine Health Foundation.

This is not a cure, and the authors are careful to frame FMT as an adjunctive therapy rather than a standalone treatment. But the signal is real, and it opens a genuinely new therapeutic avenue. The gut microbiome is modifiable. And modifying it, it seems, can change the trajectory of a skin disease that has nothing obviously to do with the gut at all.

A Case That Changed Everything:

Return, for a moment, to that Canadian Shepherd in São Paulo. His case, published in Veterinary Record Case Reports in 2026 by Dutra and colleagues at UNESP Botucatu, illustrates what is possible when the full toolkit of modern veterinary dermatology is applied thoughtfully.

After the initial assessment, which confirmed Malassezia overgrowth in both ear canals and on the skin, symptomatic therapy was initiated. Given the dog's weight (40 kg) and the owner's financial constraints, the team devised an individualised protocol: oclacitinib at 0.4 mg/kg on alternate days, alternating with prednisolone at 0.5 mg/kg on anti-inflammatory doses, followed by one drug-free day. Adjunct therapy included chlorhexidine and miconazole shampoo every three days and a hydrolysed soy-based diet. After three months, the owner reported approximately 70% improvement.

But the team did not stop there. Skin prick testing, a technique that identifies the specific allergens driving the immune response, revealed sensitisation to two grass species: Cynodon dactylon and Lolium multiflorum. Both are common in the rural environment where the dog spent most of his time. Armed with this information, the team initiated allergen-specific immunotherapy: a three-phase subcutaneous protocol with increasing allergen concentrations, designed to retrain the immune system rather than simply suppress it.

The outcome was remarkable. As ASIT took effect, oclacitinib and prednisolone were gradually withdrawn. The dog achieved complete control of pruritus and skin lesions. A dog that had scored 10 out of 10 on the itch scale, a dog that had been scratching himself raw, was, in the end, drug-free and comfortable. ASIT, the authors concluded, proved to be an effective and safe causal therapy, reducing the need for symptomatic drugs and improving quality of life.

🐕 CLINICAL LESSON:  ASIT is the only disease-modifying therapy for cAD. It addresses root cause rather than symptoms, and in the right patientm one whose allergens can be identifiedm it can achieve complete remission with drug withdrawal.

An Unexpected Ally:

Among the more surprising papers published in 2026 is a study from the Federal University of Santa Maria in Brazil, led by Carollina Mariga and published in Frontiers in Allergy. The subject: Cannabis oil as an adjunct therapy for dogs with cAD that had not responded adequately to oclacitinib alone.

The rationale is grounded in basic science. The endocannabinoid system (the network of receptors and signalling molecules that Cannabis compounds interact with) is uniquely expressed in skin tissues and cells. Cannabinoids have been shown to reduce oxidative stress and inflammation, and to modulate the immune responses that drive dermatological conditions. The question was whether this translated into clinical benefit in atopic dogs.

The study enrolled 16 dogs with cAD previously treated with oclacitinib without satisfactory improvement. 14 completed all four stages of a fixed-sequence repeated-measures protocol: T0 (oclacitinib alone), T30 (placebo plus oclacitinib), T60 (Cannabis oil plus oclacitinib at full dose), and T90 (Cannabis oil plus oclacitinib at 50% reduced dose). Dermatological assessments including CADESI-4 and owner-reported pruritus scores and were performed at each stage, with both the dermatologist and owners blinded to whether the animal was receiving placebo or Cannabis oil.

The results were nuanced but encouraging. CADESI-4 scores did not change significantly; the skin lesions themselves were not dramatically improved. But pruritus scores told a different story. There was a significant reduction in itch between T0 and T60 (p=0.0010) and between T0 and T90 (p=0.0025). Crucially, there was no significant difference between T30 (placebo) and T60 (Cannabis oil), which the authors interpret carefully: the comparison between T0 and T60 may partly reflect the cumulative effect of oclacitinib over time. But the most striking finding was at T90: with Cannabis oil added, the oclacitinib dose was reduced by 50% and pruritus control was maintained. Adverse events were mild, transient, and self-limiting.

This is preliminary data from a small study, and the authors are appropriately cautious in their conclusions. But the signal that Cannabis oil may enable meaningful dose reduction of a JAK inhibitor while maintaining pruritus control is worth watching. In a disease that requires lifelong management, any strategy that reduces drug burden without sacrificing efficacy is clinically valuable.

The Precision Medicine Vision:

Step back from the individual studies and a coherent picture emerges. Canine atopic dermatitis is entering the era of precision medicine, not as a slogan, but as a practical clinical reality. The tools now exist, or are rapidly being developed, to stratify patients, select therapies based on individual biology, and monitor outcomes in ways that were simply not possible five years ago.

The precision medicine framework for cAD rests on six pillars. The first is genetic screening: the SLAMF1 variant can now be tested for using commercial DNA panels, enabling risk stratification before clinical signs even appear and informing breeding decisions that could reduce the prevalence of the disease in future generations. The second is immunological endotyping: understanding whether a given dog has a predominantly Th2-driven disease or a mixed-axis profile can guide therapy selection, a pure Th2 dog may respond beautifully to lokivetmab's IL-31 blockade, while a mixed-axis dog may need broader immunomodulation.

The third pillar is microbiome assessment: gut dysbiosis profiling can identify candidates for FMT, leveraging the gut-skin axis to address root-cause immune dysregulation rather than simply suppressing its downstream effects. The fourth is targeted pharmacotherapy: the arrival of atinvicitinib, with its high JAK1 selectivity, means that clinicians can now choose a drug that minimises off-target immune suppression; preserving the beneficial functions of JAK2 and JAK3 while blocking the pathological JAK1-dependent cytokine signalling that drives itch and inflammation.

The fifth pillar is multimodal combination: the phased approach, using a JAK inhibitor for rapid control during flares, transitioning to lokivetmab for sustained maintenance, and layering in ASIT for long-term disease modification, represents a sophisticated, patient-centred strategy that no single drug can replicate. And the sixth pillar is owner-reported outcomes: Mars Veterinary Health's 2025 Science Impact Report highlighted the development of validated Owner Reported Outcome (ORO) instruments that systematically incorporate the pet owner's perspective into clinical care and veterinary trials, a recognition that in a chronic disease affecting the human-animal bond, the owner's experience is not a soft endpoint. It is a clinical one.

Wichtowska and Olejnik, in their 2025 review, put it plainly: future strategies for cAD will focus on patient stratification and personalised approaches based on immunological endotypes. The era of one-size-fits-all treatment for the itchy dog is ending. What is replacing it is something more demanding, and far more exciting.

The Dog That Stopped Scratching:

The Canadian Shepherd in São Paulo is drug-free now. His coat has grown back. His skin is clear. His owner no longer lies awake listening to the rhythmic sound of scratching from across the room. That outcome, achieved through careful allergen identification, a three-phase immunotherapy protocol, and the gradual withdrawal of symptomatic drugs is a testament to what is possible when science and clinical skill converge.

1. Jirjis F, Kowalski TJ, Lynn RC, et al. Efficacy and Field Safety of the Second-Generation, Highly Selective JAK1 Inhibitor Atinvicitinib for the Treatment of Canine Atopic Dermatitis: A Multicentre, Blinded, Randomised, Placebo-Controlled Clinical Trial in Client-Owned Dogs. Vet Dermatol. 2026 Sep 17. doi:10.1111/vde.70106

2. Felten V, West EA, Martini F, et al. Faecal Microbiota Transplantation Reduces Lesion Severity and Medication Use in Canine Atopic Dermatitis: A Randomised, Placebo-Controlled, Double-Blinded Clinical Trial. Vet Dermatol. 2026 Jun 12. doi:10.1111/vde.70092

3. Forman OP, Freyer J, Kerr A, et al. A splice donor variant in SLAMF1 is associated with canine atopic dermatitis. Front Vet Sci. 2025;12. doi:10.3389/fvets.2025.1550617

4. Forman OP, Freyer J, Kerr A, et al. Discovery of a SLAMF1 gene change that increases dogs' risk of developing canine atopic dermatitis: a plain language summary. Vet Q. 2026. doi:10.1080/01652176.2026.2670342

5. Mariga C, Silva FC, Schiefler OHM, et al. Clinical observations during adjunctive Cannabis treatment and subsequent oclacitinib dose reduction in dogs with atopic dermatitis. Front Allergy. 2026. doi:10.3389/falgy.2026.1852631

6. Dutra AVR, Meira J, Mazziero VG. Allergen-specific immunotherapy guided by skin prick testing in a Canadian shepherd dog with atopic dermatitis. Vet Rec Case Rep. 2026;14:e70464. doi:10.1002/vrc2.70464

7. Wichtowska A, Olejnik M. Anti-Cytokine Drugs in the Treatment of Canine Atopic Dermatitis. Int J Mol Sci. 2025;26(22):10990. doi:10.3390/ijms262210990

8. Merck Animal Health. FDA Approves NUMELVI™ (atinvicitinib tablets) for Dogs — The First and Only Second-Generation Janus Kinase (JAK) Inhibitor for the Control of Pruritus Associated with Allergic Dermatitis. Press release. February 25, 2026.

9. Bonelli M, Kerschbaumer A, et al. Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story. Ann Rheum Dis. 2024;83(2):139–160. doi:10.1136/ard-2023-223850

10. CareVet. Clinical Outcomes Report 2025: Atopic Dermatitis in Canines. 2026.

11. Hill PB, Lo A, Eden CAN, et al. Survey of the prevalence, diagnosis and treatment of dermatological conditions in small animals in general practice. Vet Rec. 2006;158:533–539.

12. Mars Veterinary Health. 2025 Science Impact Report: Pets, Purpose, Progress — Clinical Excellence through Scientific Innovation. January 2026.